Brief: Cytodyn Announces Completion Of FDA Meeting On Phase 2 Study Of Leronlimab
12/08/2024 14:07
Aug 12 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN ANNOUNCES COMPLETION OF FDA MEETING ON PHASE II
STUDY OF
LERONLIMAB IN PATIENTS WITH RELAPSED/REFRACTORY MICROSATELLITE
STABLE COLORECTAL CANCER
* INTENDS TO PROCEED WITH A SUBMISSION OF ITS FINAL STUDY
PROTOCOL
TO FDA
Source text for Eikon: ID:nGNX1qqwr0
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer